|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance decreases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Dacarbazine APEX1 protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:16373707 PMID:19470598 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
Dacarbazine results in increased expression of BIRC5 protein |
CTD |
PMID:15577328 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Dacarbazine results in increased cleavage of and results in increased activity of CASP3 protein; TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:17410615 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Dacarbazine results in increased cleavage of and results in increased activity of CASP8 protein; TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP8 protein] |
CTD |
PMID:17410615 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
[Dacarbazine co-treated with IFNA1 protein] results in increased expression of CD38 protein; [Dacarbazine co-treated with IFNA2 protein] results in increased expression of CD38 protein; Dacarbazine promotes the reaction [IFNA1 protein results in increased expression of CD38 protein] |
CTD |
PMID:11583285 PMID:14669796 PMID:16078447 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
[Dacarbazine co-treated with IFNA2 protein] results in increased expression of CD69 protein; [Dacarbazine co-treated with Isotretinoin] affects the reaction [IFNA2 protein results in increased expression of CD69 protein]; Dacarbazine affects the reaction [IFNA2 protein results in increased expression of CD69 protein] |
CTD |
PMID:14669796 PMID:17973783 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Clu |
clusterin |
affects response to substance |
ISO |
CLU protein affects the susceptibility to Dacarbazine |
CTD |
PMID:15955107 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing multiple interactions |
ISO |
CYP1A1 protein results in increased metabolism of Dacarbazine metabolite O(6)-benzylguanine inhibits the reaction [CYP1A1 protein results in increased metabolism of Dacarbazine metabolite] |
CTD |
PMID:11751525 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
CYP1A2 protein results in increased metabolism of Dacarbazine metabolite O(6)-benzylguanine inhibits the reaction [CYP1A2 protein results in increased metabolism of Dacarbazine metabolite] |
CTD |
PMID:11751525 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Epo |
erythropoietin |
decreases response to substance |
ISO |
EPO protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15743794 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Ifna1 |
interferon, alpha 1 |
multiple interactions |
ISO |
[Dacarbazine co-treated with IFNA1 protein] results in increased expression of CD38 protein; Dacarbazine promotes the reaction [IFNA1 protein results in increased expression of CD38 protein] |
CTD |
PMID:11583285 PMID:16078447 |
|
NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Dacarbazine co-treated with Dinitrochlorobenzene] results in increased expression of IFNG mRNA |
CTD |
PMID:12202904 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Dacarbazine co-treated with Dinitrochlorobenzene] results in increased expression of IL6 mRNA |
CTD |
PMID:12202904 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf1 |
interferon regulatory factor 1 |
increases expression multiple interactions |
ISO |
Dacarbazine results in increased expression of IRF1 mRNA Isotretinoin promotes the reaction [Dacarbazine results in increased expression of IRF1 mRNA] |
CTD |
PMID:17973783 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
decreases response to substance |
ISO |
MAP3K1 protein modified form results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15123733 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases response to substance |
ISO |
MAPK1 protein modified form results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15123733 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases response to substance |
ISO |
MAPK3 protein modified form results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15123733 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases response to substance |
ISO |
MCL1 protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:12787138 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases activity decreases expression affects response to substance increases response to substance decreases response to substance |
ISO |
Dacarbazine results in decreased activity of MGMT protein Dacarbazine results in decreased expression of MGMT protein MGMT protein affects the susceptibility to Dacarbazine MGMT gene mutant form results in increased susceptibility to Dacarbazine MGMT protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:10751609 PMID:11023546 PMID:12170182 PMID:12494480 PMID:14562026 PMID:15010317 PMID:15870882 More...
|
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases response to substance |
ISO |
SLC2A1 protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:17520257 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Dacarbazine co-treated with Dinitrochlorobenzene] results in increased expression of TNF mRNA |
CTD |
PMID:12202904 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP3 protein]; TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP8 protein] |
CTD |
PMID:17410615 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases secretion decreases response to substance increases expression |
ISO |
Dacarbazine results in increased secretion of VEGFA protein VEGFA protein results in decreased susceptibility to Dacarbazine Dacarbazine results in increased expression of VEGFA mRNA; Dacarbazine results in increased expression of VEGFA protein |
CTD |
PMID:12939465 PMID:15026559 PMID:15123733 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|